Sumitomo Dainippon Pharma Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sumitomo Dainippon Pharma Co., Ltd.
Public Company Edition: Bausch remains the majority shareholder, but B+L is a separate operating company. Also, Rezolute raises $130m in dual financings and BridgeBio outlines job cuts and will out-license assets to conserve cash.
Pharma’s R&D engine has been firing on all cylinders in the past year – pipeline growth in 2021 stood at nearly twice that for the previous year, pushing the number of products under active development over 20,000 for the first time.
Plus deals involving Neumora/Vanderbilt, Active Biotech/Oncode, and Bridge/Scripps.
The company is ramping up the launches of Orgovyx for prostate cancer and Myfembree for uterine fibroids, including indication and geographic expansions, and evaluating business development opportunities.
- Other Names / Subsidiaries
- Adagio Pharmaceuticals Ltd.
- Altavant Sciences
- Boston Biomedical, Inc.
- Boston Biomedical Pharma, Inc.
- Cannasat Therapeutics Inc.
- Cynapsus Therapeutics, Inc.
- Dainippon Sumitomo Pharma Co., Ltd.
- Dainippon Sumitomo Pharma Europe Ltd.
- DS Pharma Promo Co., Ltd,
- Elevation Pharmaceuticals, Inc.
- Enzyvant Therapeutics, Inc.
- Enzyvant Sciences, Ltd.
- Myovant Sciences Ltd
- Myovant Sciences GmbH
- Myovant Sciences, Inc.
- Oryx Pharmaceuticals Inc.
- SB Bioscience Co., Ltd.
- Spirovant Sciences
- Sumitomo Chemical Co., Ltd.
- Sumitomo Dainippon Pharma America, Inc. (formerly Dainippon Sumitomo Pharma America Holdings, Inc.)
- Sumitomo Dainippon Pharma Oncology, Inc.
- Sumitomo Pharmaceuticals America
- Sumitomo Pharmaceuticals (Suzhou) Co., Ltd.
- Sumitovant Biopharma
- Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.)
- Sunovion Pharmaceuticals Europe Ltd.
- Sunovion Respiratory Development Inc.
- Tolero Pharmaceuticals, Inc.
- Urovant Sciences, Inc.
- Sumitomo Pharmaceuticals Taiwan Co., Ltd.